Journal of Diagnostics Concepts & Practice >
Advances in study on diagnosis and treatment of immune-mediated necrotizing myopathy
Received date: 2024-05-06
Accepted date: 2024-05-30
Online published: 2024-06-25
Immune-mediated necrotizing myopathy (IMNM) is a significant, subtype of idiopathic inflammatory myopathy（IIM）, characterized by symmetrical proximal limb muscle weakness and markedly elevated serum creatine kinase levels. Some patients may also exhibit extra-skeletal muscle manifestations, including rashes, interstitial lung disease, and myocardial involvement. Since its international nomenclature in 2003, IMNM has gained increasing recognition among researchers and clinicians, leading to numerous scientific investigations and clinical applications. The incidence and prevalence of IMNM can vary across different geographic regions and ethnic groups. A small sample survey conducted in the United States reported an incidence of 0.83 per 100,000 and a prevalence of 1.85 per 100,000. In northern Spain, among patients positive for anti-HMGCR antibodies, the incidence was found to be 0.6 per 100,000, with a prevalence of 3 per 100,000. However, there is a notable paucity of relevant data regarding IMNM in China. Identified risk factors for IMNM include susceptibility alleles (e.g., HLA-DRB1*11), the use of statins or immune checkpoint inhibitors, and viral infections. Diagnosing IMNM requires a comprehensive evaluation that includes assessing muscle involvement symptoms, identifying myositis-specific autoantibodies, measuring creatine kinase levels, analyzing muscle biopsy pathology, and conducting related examinations. Currently, there is a lack of prospective randomized controlled studies on the treatment of IMNM. In clinical practice, glucocorticoids and traditional immunosuppressants are primarily employed on an empirical basis. For refractory cases, treatment regimens may involve rituximab and intravenous human immunoglobulin. Therapeutic strategies targeting B cells and the mechanisms underlying pathogenic autoantibody production may offer promising avenues for future treatment. This article systematically reviews the clinical characteristics, diagnostic criteria, relevant auxiliary examinations, and treatment strategies for IMNM, aiming to provide a comprehensive reference for clinicians in understanding, diagnosing, and managing this condition.
LIU Hongjiang , XIE Qibing . Advances in study on diagnosis and treatment of immune-mediated necrotizing myopathy[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(03) : 270 -277 . DOI: 10.16150/j.1671-2870.2024.03.004
| [1] | LUNDBERG I E, FUJIMOTO M, VENCOVSKY J, et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Pri-mers, 2021, 7(1):86. |
| [2] | BOHAN A, PETER J B. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347. |
| [3] | BOHAN A, PETER J B. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292(8):403-407. |
| [4] | HOOGENDIJK J E, AMATO A A, LECKY B R, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands[J]. Neuromuscul Disord, 2004, 14(5):337-345. |
| [5] | LUNDBERG I E, TJ?RNLUND A, BOTTAI M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis,2017, 76(12):1955-1964. |
| [6] | DAMOISEAUX J, MAMMEN A L, PIETTE Y, et al. 256(th) ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021[J]. Neuromuscul Disord, 2022, 32(7):594-608. |
| [7] | ALLENBACH Y, BENVENISTE O, STENZEL W, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis[J]. Nat Rev Rheumatol, 2020, 16(12):689-701. |
| [8] | ALLENBACH Y, MAMMEN A L, BENVENISTE O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28(1):87-99. |
| [9] | SHELLY S, MIELKE M M, PAUL P, et al. Incidence and prevalence of immune-mediated necrotizing myopathy in adults in Olmsted County, Minnesota[J]. Muscle Nerve, 2022, 65(5):541-546. |
| [10] | PRIETO-PE?A D, OCEJO-VINYALS J G, MAZARIEGOS-CANO J, et al. Epidemiological and genetic features of anti-3?hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review[J]. Eur J Intern Med, 2022, 101:86-92. |
| [11] | WANG C H, LIANG W C. Pediatric immune-mediated necrotizing myopathy[J]. Front Neurol, 2023, 14:1123380. |
| [12] | ROTHWELL S, CHINOY H, LAMB J A, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups[J]. Ann Rheum Dis, 2019, 78(7):996-1002. |
| [13] | OHNUKI Y, SUZUKI S, URUHA A, et al. Association of immune-mediated necrotizing myopathy with HLA polymorphisms[J]. Hla, 2023, 101(5):4494-57. |
| [14] | ADLER B, CHRISTOPHER-STINE L, TINIAKOU E. Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy[J]. BMJ Case Rep, 2022, 15(5):e248880. |
| [15] | PARKER B A, CAPIZZI J A, GRIMALDI A S, et al. Effect of statins on skeletal muscle function[J]. Circulation, 2013, 127(1):96-103. |
| [16] | MAMMEN A L, PAK K, WILLIAMS E K, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limi-ted musculoskeletal side effects[J]. Arthritis Care Res (Hoboken), 2012, 64(2):269-272. |
| [17] | KAO J C, LIAO B, MARKOVIC S N, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies[J]. JAMA Neurol, 2017, 74(10):1216-1222. |
| [18] | TAN C Y, TOH T H, TOH Y F, et al. A temporal association between COVID-19 vaccination and immune-mediated necrotizing myopathy[J]. Muscle Nerve, 2022, 65(6):E24-E26. |
| [19] | TSUZUKI WADA T, YOKOTA K, INAYOSHI F, et al. New-onset immune-mediated necrotizing myopathy and trigeminal neuropathy after SARS-CoV-2 mRNA vaccination in a patient with rheumatoid arthritis and sjogren's syndrome[J]. Intern Med, 2023, 62(24):3699-3706. |
| [20] | DODIG D, TARNOPOLSKY M A, MARGETA M, et al. COVID-19-associated critical illness myopathy with direct viral effects[J]. Ann Neurol, 2022, 91(4):568-574. |
| [21] | WATANABE Y, URUHA A, SUZUKI S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87(10):1038-1044. |
| [22] | YANG H, TIAN X, ZHANG L, et al. Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort[J]. BMC Musculoskelet Disord, 2022, 23(1):425. |
| [23] | XU L, YANG M G, HU L, et al. Anti-signal recognition particle positive necrotizing myopathy-sjogren's syndrome overlap syndrome: a descriptive study on clinical and myopathology features[J]. BMC Musculoskelet Disord, 2023, 24(1):219. |
| [24] | MA X, XU L, JI S, et al. The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China[J]. Front Neurol, 2021, 12:670784. |
| [25] | WILLIAMS B, HORN M P, BANZ Y, et al. Cutaneous involvement in anti-HMGCR positive necrotizing myopathy[J]. J Autoimmun, 2021, 123:102691. |
| [26] | GE Y, YANG H, XIAO X, et al. Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies[J]. BMC Pulm Med, 2022, 22(1):14. |
| [27] | YANG H, LI W, TIAN X, et al. Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies[J]. Ann Rheum Dis, 2022, 81(3):e48. |
| [28] | KHAN O A, WILCHES R M, MEHRABI J N, et al. Evidence of cardiac involvement in a patient with necroti-zing autoimmune myopathy (NAM)[J]. Cureus, 2023, 15(8):e44106. |
| [29] | LIU M, LIN Y, QIAO L, et al. Characteristics of cardiac involvement in immune-mediated necrotizing myopathy[J]. Front Immunol, 2023, 14:1094611. |
| [30] | CHEN J, LIN D L, LIN A Y. A case of meningoencephalomyelitis associated with immune-mediated necrotizing myopathy[J]. Neurol Sci, 2022, 43(11):6585-6588. |
| [31] | HUANG L Y, PENG Y J, SUNG Y F. Anti-SRP myopathy with sensorimotor polyneuropathy: a case report[J]. Acta Neurol Taiwan, 2023, 32(4):212-217. |
| [32] | LI J, YAN M, QIN J, et al. Deep venous thrombosis in an individual with statin-exposed anti-SRP myopathy: case report and review of literature[J]. Thromb J, 2021, 19(1):92. |
| [33] | SAKAI K, TAKAHASHI M, ITO Y, et al. Thrombotic microangiopathy in a patient with anti-signal recognition particle antibody-positive immune-mediated necrotizing myopathy[J]. Int J Rheum Dis, 2024, 27(1):e14942. |
| [34] | ALLENBACH Y, KERAEN J, BOUVIER A M, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody[J]. Brain, 2016, 139(Pt 8):2131-2135. |
| [35] | SHELLY S, BEECHER G, MILONE M, et al. Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation[J]. Rheumatology (Oxford), 2022, 62(1):281-289. |
| [36] | ALLENBACH Y, MAMMEN A L, BENVENISTE O, et al. Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necroti-zing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28(1):87-99. |
| [37] | PINAL-FERNANDEZ I, CASAL-DOMINGUEZ M, MAMMEN A L. Immune-mediated necrotizing myopathy[J]. Curr Rheumatol Rep, 2018, 20(4):21. |
| [38] | WALTER P, BLOBEL G. Signal recognition particle contains a 7S RNA essential for protein translocation across the endoplasmic reticulum[J]. Nature, 1982, 299(5885):691-698. |
| [39] | QIU R, WANG Z, WEI X, et al. The pathogenesis of anti-signal recognition particle necrotizing myopathy: A Review[J]. Biomed Pharmacother, 2022, 156:113936. |
| [40] | SUZUKI S, NISHIKAWA A, KUWANA M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients[J]. Orphanet J Rare Dis, 2015, 10:61. |
| [41] | ZHENG Y, ZHAO Y, HAO H, et al. What should we expect when two myositis-specific antibodies coexist in a patient[J]. Eur J Med Res, 2023, 28(1):429. |
| [42] | FRIESEN J A, RODWELL V W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases[J]. Genome Biol, 2004, 5(11):248. |
| [43] | BENVENISTE O, DROUOT L, JOUEN F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy[J]. Arthritis Rheum, 2011, 63(7):1961-1971. |
| [44] | DROUOT L, ALLENBACH Y, JOUEN F, et al. Explo-ring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies[J]. Arthritis Res Ther, 2014, 16(1):R39. |
| [45] | TSENG C W, SATOH M, HASEGAWA T, et al. Analytic and clinical validity of myositis-specific antibodies by line-blot immunoassay is essential[J]. J Clin Rheumatol, 2024, 30(1):e23-e28. |
| [46] | MERLONGHI G, ANTONINI G, GARIBALDI M. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge[J]. Autoimmun Rev, 2022, 21(2):102993. |
| [47] | KIMURA M, AIZAWA A, KUDOU R, et al. Differences in muscle magnetic resonance imaging findings between anti-signal recognition particle antibody-positive myopathy and anti-aminoacyl-tRNA synthetase antibody-positive myositis[J]. Clin Exp Rheumatol, 2024, 42(2):321-328. |
| [48] | WEI P, ZHONG H, XIE Q, et al. Machine learning-based radiomics to differentiate immune-mediated necrotizing myopathy from limb-girdle muscular dystrophy R2 using MRI[J]. Front Neurol, 2023, 14:1251025. |
| [49] | KUBOTA A, SHIMIZU J, UNUMA A, et al. Alanine transaminase is predominantly increased in the active phase of anti-HMGCR myopathy[J]. Neuromuscul Disord, 2022, 32(1):25-32. |
| [50] | URUHA A, NOGUCHI S, SATO W, et al. Plasma IP-10 level distinguishes inflammatory myopathy[J]. Neurology, 2015, 85(3):293-294. |
| [51] | DE PAEPE B, BRACKE K R, DE BLEECKER J L. Retrospective study shows that serum levels of chemokine CXCL10 and cytokine GDF15 support a diagnosis of sporadic inclusion body myositis and immune-mediated necrotizing myopathy[J]. Brain Sci, 2023, 13(10):1369. |
| [52] | YANG M G, ZHANG Q, WANG H, et al. The accumulation of muscle RING finger-1 in regenerating myofibers: Implications for muscle repair in immune-mediated necrotizing myopathy[J]. Front Neurol, 2022, 13:1032738. |
| [53] | HANAOKA B Y, PETERSON C A, HORBINSKI C, et al. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies[J]. Nat Rev Rheumatol, 2012, 8(8):448-457. |
| [54] | RADEMACHER J G, GLAUBITZ S, ZECHEL S, et al. Treatment and outcomes in anti-HMG-CoA reductase-associated immune-mediated necrotising myopathy. Comparative analysis of a single-centre cohort and published data[J]. Clin Exp Rheumatol, 2022, 40(2):320-328. |
| [55] | WANG J X, WILKINSON M, OLDMEADOW C, et al. Outcome predictors of immune-mediated necrotizing myo-pathy-a retrospective, multicentre study[J]. Rheumato-logy (Oxford), 2022, 61(9):3824-3829. |
| [56] | KOCOLOSKI A, MARTINEZ S, MOGHADAM-KIA S, et al. Role of intravenous immunoglobulin in necrotizing autoimmune myopathy[J]. J Clin Rheumatol, 2022, 28(2):e517-e520. |
| [57] | ZHANG H, SUN Y, LIU H, et al. Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series[J]. Rheumatology (Oxford), 2022, 61(6):2625-2630. |
| [58] | CHEN S, YANG J, HE D, et al. Anti-SRP immune-media-ted necrotizing myopathy responsive to ofatumumab: a case report[J]. Front Immunol, 2023, 14:1301109. |
| [59] | CUI B B, TIAN Y R, MA X Y, et al. Belimumab for immune-mediated necrotizing myopathy associated with anti-SRP antibodies: a case report and retrospective review of patients treated with anti-B-cell therapy in a single center and literature[J]. Front Immunol, 2021, 12:777502. |
| [60] | WEN C, YANG J, WEI D, et al. Anti-signal recognition particle antibody-positive immune-mediated necrotizing myopathy treated with ofatumumab[J]. Rheumatology (Oxford), 2024, 63(2):e53-e55. |
| [61] | LI S, LI W, JIANG W, et al. The efficacy of tocilizumab in the treatment of patients with refractory immune-media-ted necrotizing myopathies: an open-label pilot study[J]. Front Pharmacol, 2021, 12:635654. |
| [62] | JULIEN S, VADYSIRISACK D, SAYEGH C, et al. Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model[J]. Biomedicines, 2022, 10(8):2036. |
| [63] | MAMMEN A L, AMATO A A, DIMACHKIE M M, et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet Rheumatol, 2023, 5(2):e67-e76. |
| [64] | JULIEN S, VAN DER WONING B, DE CEUNINCK L, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy[J]. Rheumatology (Oxford), 2023, 62(12):4006-4011. |
| [65] | QIN C, DONG M H, ZHOU L Q, et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy[J]. Proc Natl Acad Sci U S A, 2024, 121(6):e2315990121. |
| [66] | DE OLIVEIRA D S, BRUNA PIRES BORGES I, KAZUE NAGAHASHI MARIE S, et al. Exercise training attenuates skeletal muscle fat infiltration and improves insulin pathway of patients with immune-mediated necrotizing myopathies and dermatomyositis[J]. Arch Rheumatol, 2023, 38(2):189-199. |
/
| 〈 |
|
〉 |
